UNSPSC 51172333: Sugammadex sodium

This classification denotes a protective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ERJ6X2MXV7. European Medicines Agency schedules Sugammadex sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32205. Sugammadex sodium generally arises in the molecular formula C72H104O48S8.8NA. The term 'sugammadex sodium' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule sugammadex sodium under HS 29329985 and SITC 51569.

Sugammadex sodium bears US NLM identifiers UMLS ID C2350811 and NCI Concept Code C78123. SMILES: As of Q4 2014, SUGAMMADEX SODIUM remains US FDA's Preferred Term for this commodity.

UNSPSC 51172333 Sugammadex sodium is a Commodity code that does not align with recent state and local procurement activity under this designation. The four most recent opportunities tagged to this code involve offender drug testing services, water treatment chemicals, pharmacy benefit management programs, and generic pharmaceutical distribution through a multistate cooperative—none of which involve sugammadex sodium or related neuromuscular blocking agent reversal products. The code shows no relevant recent solicitation activity and appears to reflect a mismatch between the commodity's nominal scope and what state and local governments are actually procuring under this taxonomy entry.

The geographic spread and issuing bodies across these unrelated opportunities span Texas (Collin County Community Supervision and Corrections Department; Texas Health and Human Services Commission), California (Orange County Public Works), and a multistate cooperative administered by Minnesota (MMCAP, serving Minnesota, Oregon, and participating jurisdictions). Representative recent solicitations include Collin County's RFP 2026-327 for offender specimen collection and drug testing services due July 23, 2026, estimated at $600,000 over two years; Orange County's IFB 080-3008401-RE for sodium hypochlorite and sulfuric acid due March 27, 2026; and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026. None of these activities relate to sugammadex sodium procurement. Firms pursuing this code should verify whether state and local procurement offices have correctly tagged opportunities under this commodity or whether activity in neuromuscular reversal agents exists under a different UNSPSC classification.